The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.
The Consumer Healthcare Products Association on Friday morning honored longtime industry veteran Pat Lonergan, co-founder of Numark Labs, with its Ivan D. Combe Lifetime Achievement Award for his contributions in the advancement of the business of over-the-counter medicines.
According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, more than half of all parents reported feeling anxious, fearful or helpless when their child comes down with a fever.
The Food and Drug Administration has approved a drug made by Merck for Type 2 diabetes, the drug maker said. Merck announced the approval of Janumet XR (sitagliptin and metformin hydrochloride) extended-release tablets as a once-daily treatment for the disease.
Clarinex (desloratadine), the next-generation prescription allergy remedy to the second-generation Claritin, is 1-of-3 blockbuster prescription medicines that may make the crossover from prescription-only to over-the-counter in the near future.
Managed care and prescription plans are working to switch patients to generic versions of Pfizer's Lipitor despite the drug maker's efforts to reduce costs for the branded version, a new study suggested.
Pfizer is partnering with a division of Johnson & Johnson and a charity organization to launch an initiative to award funding to projects designed to improve the diagnostic identification and tracking of Alzheimer's disease.
The National Advertising Review Board on Tuesday recommended that Novartis Consumer Health discontinue advertising claims that the company’s Excedrin Extra Strength product starts relieving headache pain faster than Advil.
One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.